SLN · Silence Therapeutics plc

$13.72 -0.25 (-1.79%) At close · Aug 14

Market Cap

$1.94B

141.74M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Craig Tooman	Former Chief Executive Officer	$690,687	—	—	$1,528,263	—	$27,913	$2,246,863
Iain Ross	Interim Principal Executive Officer	$17,041	—	—	$1,257,000	—	—	$1,274,041
Rhonda Hellums	Executive Vice President, Chief Financial Officer	$490,000	—	—	$637,991	—	$22,932	$1,150,923
Steven Romano	Executive Vice President, Chief of Research and Development	$490,000	—	—	$485,235	—	$6,667	$981,902

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Craig Tooman	Chief Executive Officer	$618,844	—	—	$2,689,796	$352,741	$32,589	$3,693,970
Rhonda Hellums	Executive Vice President, Chief Financial Officer	$466,013	—	—	$985,688	$188,485	$22,632	$1,662,818
Steven Romano	Executive Vice President, Chief of Research and Development	$465,750	—	—	$929,824	$188,385	$8,334	$1,592,293

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Craig Tooman	Chief Executive Officer	$589,375	—	—	$7,636,244	$840,938	$33,412	$9,099,969
Rhonda Hellums	Executive Vice President, Chief Financial Officer	$430,500	—	—	$2,223,112	$409,500	$21,732	$3,084,844
Steven Romano	Executive Vice President, Chief of Research and Development	$322,500	—	—	$1,618,641	$193,500	$3,696	$2,138,337

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Craig Tooman	Chief Executive Officer	$557,118	—	—	$5,264,235	$136,000	$81,912	$6,039,265
Rhonda Hellums	Executive Vice President, Chief Financial Officer	$403,958	—	—	$1,890,202	$69,165	$20,164	$2,383,489

Executive changes

Person	Role	Change	Effective	Filed
Rhonda Hellums	Executive Director	Appointed	2025-12-18	2025-12-22
Iain Ross	interim principal executive officer	Appointed	2025-12-14	2025-12-15
James Ede-Golightly	director	Appointed	2025-12-14	2025-12-15
Craig Tooman	member of the Company's Board of Directors	Resigned	2025-12-14	2025-12-15
Craig Tooman	President, Chief Executive Officer and a member of the Company's Board of Directors	Resigned	2025-12-14	2025-12-15
Iain Ross	member of the Audit and Risk Committee	Appointed	—	2025-08-14
Michael Davidson	member of the Board	Resigned	2025-08-11	2025-08-14
Tim McInerney	Chair of the Remuneration Committee	Appointed	2025-05-05	2025-05-06
Tim McInerney	Director	Appointed	2025-05-05	2025-05-06

Key facts CIK 1479615 CUSIP 82686Q101 13F (30d) 73 filings 72 filers Visit website Investor relations